Cure Duchenne Hosts Drisapersen Update Webinar With GSK on May 6, 2013

  Cure Duchenne Hosts Drisapersen Update Webinar With GSK on May 6, 2013

Business Wire

NEWPORT BEACH, Calif. -- April 30, 2013

CureDuchenne, a nonprofit that raises awareness and funds research to find a
cure for Duchenne muscular dystrophy, will host a webinar on drisapersen with
GlaxoSmithKline (GSK) on May 6, 2013 at 12 p.m. EDT for Duchenne parents and
advocates. The purpose of the webinar is to update the Duchenne community
about Phase II clinical trial results for GSK’s drisapersen drug for the
treatment of Duchenne muscular dystrophy, a progressive muscle wasting disease
that impacts 1 in 3,500 boys. GSK investigator John Kraus will present and
answer submitted questions.

CureDuchenne is hosting the webinar in collaboration with Parent Project
Muscular Dystrophy and the Muscular Dystrophy Association to enable the
Duchenne community and GSK to come together to further understand the
drisapersen update for potential Duchenne treatments. Boys with Duchenne are
usually diagnosed before the age of 5, in a wheelchair by age 12 and most
don’t survive their mid-20s. There is currently no cure for Duchenne.

To register for the “Drisapersen Update” webinar with the GSK on May 6 click
here.

Follow us on Facebook, Twitter and YouTube.

About CureDuchenne

CureDuchenne is a national nonprofit organization located in Newport Beach,
Calif., dedicated to finding a cure for Duchenne, the most common and most
lethal form of muscular dystrophy. As the leading genetic killer of young
boys, Duchenne affects more than 300,000 boys worldwide.

CureDuchenne has garnered international attention for its efforts to raise
funds and awareness for Duchenne. With the help of CureDuchenne’s
distinguished international panel of Scientific Advisors, funds raised by
CureDuchenne support the most promising research aimed at treating and curing
Duchenne. To date, seven CureDuchenne research projects have made their way
into human clinical trials – a unique accomplishment as few health-related
nonprofits have been successful in being a catalyst for human clinical trials.

Contact:

CureDuchenne
Karen Harley, 949-872-2552
 
Press spacebar to pause and continue. Press esc to stop.